Five things to know:
1. Myelomeningocele, the most severe form of spinal bifida, is a birth defect that affects 1 in every 4,000 children in the U.S.
2. Researchers induced 116 pregnant rats with fetal myelomeningocele and injected human amniotic fluid stem cells in each of their amniotic cavities.
3. The hAFSCs mitigated to the lesions and covered the spinal cords as well as releasing hepatocyte growth factor to protect neural elements and promote neural regeneration.
4. The study showed that in utero therapy with hAFSCs may be effective in treating fetal myelomeningocele.
5. Author of the study Yushi Abe, MD, of Keio University School of Medicine in Tokyo aims to start research for human clinical application.
More articles on biologics:
Misonix ultrasonic device earns CE Mark approval — 4 insights
Laser Spine Institute co-founders now owe ex-business partner $300M+, judge rules
Academic panel to define best practices for outpatient stem cell procedure
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
